Welcome to our dedicated page for Bioatla news (Ticker: BCAB), a resource for investors and traders seeking the latest updates and insights on Bioatla stock.
BioAtla, Inc. (Nasdaq: BCAB) is a global clinical-stage biotechnology company developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors, and its news flow reflects the progress of this platform. Company announcements regularly describe updates on CAB-based antibody-drug conjugates and bispecific T-cell engagers, regulatory interactions, financing arrangements, and strategic collaborations.
Recent BioAtla news has highlighted the clinical and regulatory path for ozuriftamab vedotin (Oz-V), a CAB-Platform ROR2-targeting ADC. Releases describe compelling Phase 2 data in HPV-positive oropharyngeal squamous cell carcinoma (OPSCC), FDA Fast Track Designation for certain squamous cell carcinoma of the head and neck patients, and FDA alignment on a randomized Phase 3 trial design with dual primary endpoints. Additional coverage explains a special purpose vehicle (SPV) transaction with Inversagen AI, LLC and GATC Health Corp. intended to fund a registrational Oz-V trial in OPSCC while BioAtla retains a majority ownership interest in the Oz-V asset.
News items also focus on mecbotamab vedotin (Mec-V), a CAB AXL-targeting ADC in Phase 2 development, including clinical data in treatment-refractory soft tissue sarcomas and mKRAS non-small cell lung cancer. For BA3182, a CAB EpCAM x CAB CD3 bispecific T-cell engager, BioAtla has reported preliminary Phase 1 results in metastatic adenocarcinoma patients, describing a manageable safety profile and prolonged tumor control at higher dose levels.
Investors following BCAB news will also see regular updates on financial results, cash runway, and capital structure. The company has announced Pre-Paid Advance Agreements and a Standby Equity Purchase Agreement that provide flexible equity-linked financing, as well as a special meeting of stockholders to consider approval of potential share issuances and a possible reverse stock split. Additional releases discuss Nasdaq listing compliance milestones, patent coverage, and licensing agreements such as the worldwide license to Context Therapeutics for a CAB Nectin-4 x CD3 T-cell engager.
For those tracking oncology pipelines, regulatory milestones, and financing developments in clinical-stage biotech, the BioAtla news page offers ongoing detail on how the CAB platform and its lead programs are progressing. Investors and observers can use this stream of press releases to monitor trial design decisions, data presentations at major medical congresses, partnership activity and key corporate events related to BCAB stock.
BioAtla (BCAB) reported its Q4 and full year 2024 financial results, highlighting progress in its clinical programs. The company's CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 study continues with data readout expected mid-2025.
Key highlights include mecbotamab vedotin showing exceptional overall survival in mKRAS NSCLC patients, with 66% one-year and 58% two-year survival rates. Ozuriftamab vedotin demonstrated 45% ORR in HPV-positive SCCHN patients.
Financial results show Q4 2024 R&D expenses of $11.6M (down from $22.7M in Q4 2023) and G&A expenses of $4.6M (down from $5.9M). Net loss was $14.9M compared to $26.9M in Q4 2023. The company ended 2024 with $49.0M in cash, implementing a 30% workforce reduction to extend runway beyond key clinical readouts in 1H 2026.
BioAtla (Nasdaq: BCAB), a global clinical-stage biotechnology company specializing in Conditionally Active Biologic (CAB) antibody therapeutics for solid tumor treatment, has announced two upcoming poster presentations at prestigious medical conferences.
The company will present at the European Lung Cancer Congress (ELCC) 2025 in Paris, France (March 26-29, 2025) and the Mayo Clinic Multidisciplinary Head and Neck Cancer Symposium 2025 in Scottsdale, Arizona (March 27-29, 2025). The presentation materials will be made available on BioAtla's website under the 'Publication' section following the conferences.
BioAtla (BCAB), a global clinical-stage biotechnology company specializing in Conditionally Active Biologic (CAB) antibody therapeutics for solid tumor treatment, has scheduled its Fourth Quarter and Full-Year 2024 financial results announcement for March 27, 2025.
The company will host a conference call and webcast at 4:30 p.m. ET to discuss financial performance and provide business updates. Interested parties can access the call through domestic (800-245-3047) or international (203-518-9765) dial-in numbers using the Conference ID: BIOATLA.
BioAtla (NASDAQ: BCAB) has announced a registered direct offering of 9,679,158 common stock shares, each accompanied by a warrant to purchase one share at $1.19. The combined offering price is $0.9520 per share and warrant. The warrants will be exercisable after six months and expire in 5.5 years.
The offering is expected to generate approximately $9.2 million in gross proceeds, closing around December 20, 2024. The funds will support research and development initiatives, including key clinical programs: BA3182 Phase 1 dose escalation data (2Q25) and Phase 2 expansion data (1H26), and mecbotamab vedotin Phase 2B data in mKRAS NSCLC (1H26). Tungsten Advisors acted as the sole placement agent.
BioAtla presented data on Mecbotamab Vedotin (Mec-V) at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting. The study focused on patients with advanced non-small cell lung cancer (NSCLC) expressing mutated KRAS (mKRAS).
Results indicated improved median overall survival (OS) for Mec-V treated patients with mKRAS compared to wild-type KRAS (wtKRAS). One-year OS was 58% for mKRAS patients versus 23% for wtKRAS patients. Mec-V showed antitumor activity across 9 different mKRAS variants.
Key data highlights from the Phase 2 trial (NCT04681131) include:
- 78 patients enrolled, received Mec-V monotherapy or Mec-V + nivolumab.
- Patients had a median of 3 prior lines of therapy.
- 24 patients (30.7%) had mKRAS NSCLC.
- Median OS was not reached for mKRAS patients vs. 8.7 months for wtKRAS patients.
- 6 responses among 21 efficacy-evaluable mKRAS patients (ORR=28.6%).
AXL expression was highly associated with mKRAS NSCLC. Treatment was well tolerated with a manageable safety profile. A randomized trial of Mec-V in treatment-refractory mKRAS NSCLC is planned for 2025.
BioAtla (Nasdaq: BCAB), a clinical-stage biotechnology company, announced a poster presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting in Washington, DC, from December 13–15, 2024.
The presentation, titled Characterization of Mutated KRAS Genotype and Clinical Outcomes in Patients With Advanced NSCLC Treated With Mecbotamab Vedotin, a CAB-AXL-ADC, will be delivered by a team of authors including Julia Rotow, Grace K. Dy, and others.
Details of the presentation include:
- Poster Number: PP01.03
- Session Type: Poster Reception
- Session Date and Time: Saturday, December 14, 2024, from 5:40 P.M. – 6:40 P.M. ET
Materials from the presentation will be available on the “Publication” section of BioAtla’s website after the event.
BioAtla (BCAB) reported Q3 2024 financial results and clinical progress. Key highlights include promising data from ozuriftamab vedotin Phase 2 trial in head and neck cancer showing 9-month median overall survival, and evalstotug demonstrating tumor reduction in melanoma patients. The company received FDA guidance for potential registrational trials in 2025. Q3 net loss was $10.6M, with revenue of $11.0M from a licensing agreement. R&D expenses decreased to $16.4M from $28.4M year-over-year. Cash position of $56.5M is expected to fund operations into early 2026.
BioAtla (BCAB), a clinical-stage biotechnology company developing Conditionally Active Biologic antibody therapeutics for solid tumors, will host a conference call and webcast on November 7, 2024, at 4:30 p.m. ET to discuss its third quarter 2024 financial results and business highlights. The financial results press release will be available before the conference call on the company's website. A replay will be accessible through the Investors section.
BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumor treatment, has announced a poster presentation at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting. The event will take place from November 8–10, 2024, at the George R. Brown Convention Center in Houston, TX.
The presentation, titled 'Updated results from a phase 1 study of evalstotug (BA3071), an anti-CTLA-4 conditionally active biologic, with or without nivolumab, in advanced solid tumors', is scheduled for Friday, November 8, 2024, at 9:00a CDT in Exhibit Halls AB. The presentation materials will be available on the 'Publication' section of BioAtla's website after the presentation concludes.
BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors, has announced an upcoming oral presentation at the Society for Melanoma Research 21st International Congress (SMR) in New Orleans, LA, from October 10–13, 2024.
The presentation details are as follows:
- Title: Evalstotug (BA3071): a potent conditionally active biologic (CAB) anti-CTLA-4 antibody designed to enable high exposures, extended dosing, and reduced immune-mediated toxicity
- Presenting Author: William Boyle, Ph.D.
- Session Category: Developmental Immunotherapy
- Date & Time: Friday, October 11th, 2024 from 8:00am–10:20am CDT
The abstract will be published in the 2024 SMR Abstract book and online in the PCMR journal. Presentation materials will be available on BioAtla's website after the presentation concludes.